Acarix AB, a Swedish/Danish commercial stage medical device company, has today successfully listed its shares on Nasdaq First North Premier (“Nasdaq First North Premier”) in Stockholm in an initial public offering.

Acarix AB has raised SEK 140 million in connection with the offering. The funds will mainly be allocated to launch the company’s new commercial strategy, including the onboarding of sales people. A minor part of the funding will be allocated to the ongoing development of Acarix’s CADScor-system, which increases the chances of discovering Blood Clots in time.

Acarix , CADScor®System and cardiac sound measurement

Acarix was established in 2009 as a spinoff company from Coloplast A/S. Since 2010, key investors Seed Capital (DK) and Sunstone Life Science Ventures (DK) have financed the development of the company and supported it towards market introduction. While some founders remain in the company, Acarix has attracted a highly experienced management team who have held senior positions in international medical device companies.

Bruun & Hjejle acted as Danish legal advisor to Acarix in connection with the preparation of the initial public offering.